The MPH group has been able to position itself on the market with the development, production and sale of generics with its subsidiary HAEMATO PHARM AG. In addition the group was able to gain a significant market share in the segment of branded pharmaceuticals. In both business fields, generics and branded products, sustaining turnover and profit growth was generated.

Among the products, the focus has so far been on the field of oncology. Additionally the product assortment is continuously being broadened by the fields of HIV, neurology, cardiovascular disease, lifestyle products and rheumatology.

The pharmaceutical market is considered as the strongest and most safe growth market worldwide. Progress in medical innovation and increasing life expectancy are driving growth.

EU branded pharmaceuticals and generics have become an important pillar in the German pharmaceutical system because they ensure an affordable supply at the highest quality standards. With the double competence in the production and sale of generics and EU branded pharmaceuticals, MPH has created, with its subsidiary HAEMATO PHARM AG, substantial savings for the German health system, especially for pharmacies, health insurers and patients.

With its subsidiary HAEMATO Vet GmbH the MPH group does serve the veterinary market with veterinary pharmaceutical and medical products as well as animal complement feed.